Catalent, Inc. (NYSE:CTLT) Shares Sold by IFM Investors Pty Ltd

IFM Investors Pty Ltd decreased its holdings in Catalent, Inc. (NYSE:CTLT) by 3.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,432 shares of the company’s stock after selling 1,111 shares during the period. IFM Investors Pty Ltd’s holdings in Catalent were worth $2,086,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Greenleaf Trust grew its stake in shares of Catalent by 10.7% during the third quarter. Greenleaf Trust now owns 4,294 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Catalent by 12.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 9,745 shares of the company’s stock worth $590,000 after purchasing an additional 1,058 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock worth $1,179,000 after purchasing an additional 220 shares in the last quarter. Kapitalo Investimentos Ltda acquired a new position in shares of Catalent during the third quarter worth $808,000. Finally, Creative Planning grew its stake in shares of Catalent by 21.4% during the third quarter. Creative Planning now owns 6,935 shares of the company’s stock worth $420,000 after purchasing an additional 1,222 shares in the last quarter.

Catalent Price Performance

Shares of NYSE:CTLT opened at $59.09 on Monday. The company has a 50-day simple moving average of $60.12 and a 200-day simple moving average of $57.89. Catalent, Inc. has a one year low of $31.80 and a one year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The stock has a market capitalization of $10.69 billion, a price-to-earnings ratio of -9.69, a PEG ratio of 2.14 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. On average, analysts predict that Catalent, Inc. will post 0.95 EPS for the current year.

Insider Transactions at Catalent

In other news, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,642 shares of company stock worth $217,860 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CTLT. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com began coverage on shares of Catalent in a research report on Saturday, October 12th. They issued a “hold” rating for the company. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.